GO:0061179 negative regulation of insulin secretion involved in cellular response to glucose stimulus: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061179 describes any process that decreases the frequency, rate or extent of regulated insulin release that contributes to a cell's response to glucose.
• This term is a biological_process child of negative regulation of insulin secretion and is specific to the glucose-stimulated context.
• Key molecular brakes include ion channels such as TRPM4, which modulates membrane depolarization and insulin granule exocytosis.
• The cytoskeleton, small GTPases and SNARE proteins are core effectors whose regulation can suppress or tune biphasic insulin-granule exocytosis.
• Dysregulation of this negative control contributes to hyperinsulinism, type 2 diabetes and metabolic syndrome.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to causally test candidate negative regulators.
Description
GO:0061179, negative regulation of insulin secretion involved in cellular response to glucose stimulus, is a Gene Ontology biological_process term that captures the cellular brakes on glucose-triggered insulin release. The regulated release of insulin from pancreatic beta-cells is a tightly controlled process, and the ability to decrease the frequency, rate or extent of that release in response to glucose is as important as the ability to stimulate it. This term therefore describes the molecular and cellular events that dampen insulin exocytosis specifically within the context of a glucose stimulus. Understanding this process is critical because loss of negative control can lead to excessive insulin secretion, while excessive negative regulation can contribute to insufficient insulin release and hyperglycemia. Researchers studying beta-cell physiology, diabetes, and metabolic disease need precise tools to dissect which genes and pathways act as negative regulators of glucose-stimulated insulin secretion. The QuickGO definition provides the authoritative scope: any process that decreases the frequency, rate or extent of the regulated release of insulin that contributes to the response of a cell to glucose. This article integrates that definition with verified literature on insulin granule exocytosis and ion channel control to provide a research-grade overview of GO:0061179, its mechanisms, key genes, disease relevance, and the CRISPR-based methods used to study it.
negative regulation of insulin secretion involved in cellular response to glucose stimulus At A Glance
| GO ID | GO:0061179 |
|---|---|
| GO term | negative regulation of insulin secretion involved in cellular response to glucose stimulus |
| Ontology | biological_process |
| Synonym | negative regulation of insulin secretion in response to glucose; negative regulation of insulin secretion involved in cellular response to glucose |
| Definition | Any process that decreases the frequency, rate or extent of the regulated release of insulin that contributes to the response of a cell to glucose. |
| Major function | Dampening glucose-stimulated insulin exocytosis from pancreatic beta-cells |
| Parent term | negative regulation of insulin secretion |
| Related processes | Insulin granule exocytosis, biphasic secretion, beta-cell electrical activity |
| Cellular context | Pancreatic beta-cells, insulin secretory granules, plasma membrane |
What Is GO:0061179?
In simple terms, GO:0061179 is the set of cellular processes that put the brakes on insulin release when a cell is responding to glucose. More formally, it is any process that decreases the frequency, rate or extent of the regulated release of insulin that contributes to the response of a cell to glucose. This is a biological_process term and is a more specific child of negative regulation of insulin secretion, restricted to the glucose-stimulated context. It includes molecular events such as ion channel activity that reduces beta-cell excitability, changes in cytoskeletal dynamics that limit granule access to the membrane, and modulation of SNARE-mediated fusion that lowers exocytosis.
Why Is negative regulation of insulin secretion involved in cellular response to glucose stimulus Important in Cell Biology?
GO:0061179 matters because insulin secretion must be restrained as well as triggered. Without negative regulation, glucose-stimulated insulin release can become excessive or poorly timed, contributing to hyperinsulinism and metabolic dysregulation. Conversely, overactive negative regulation can suppress insulin output and worsen hyperglycemia. The molecular players that mediate this brake, including ion channels such as TRPM4 and the cytoskeletal and SNARE machinery that controls granule exocytosis, are therefore high-value targets for understanding beta-cell failure and for developing therapeutic strategies.
• Defines the cellular brakes on glucose-stimulated insulin release, a core homeostatic mechanism.
• Loss of negative regulation can cause excessive insulin secretion and hypoglycemia.
• Overactive negative regulation can contribute to insufficient insulin release and hyperglycemia.
• TRPM4 is a key ion channel that controls beta-cell excitability and insulin secretion.
• Cytoskeletal dynamics and small GTPases modulate biphasic insulin-granule exocytosis.
• SNARE proteins are terminal effectors whose regulation can suppress exocytosis.
• Provides a framework for interpreting GWAS and transcriptomic signals in type 2 diabetes.
• Guides CRISPR screens to identify causal negative regulators of insulin secretion.
• Supports drug target validation for hyperinsulinism and diabetes.
• Enables mechanistic comparison of first-phase versus second-phase insulin release.
What Happens During negative regulation of insulin secretion involved in cellular response to glucose stimulus?
Glucose sensing and the need for a brake
In simple terms: When glucose enters a beta-cell, the cell gets excited and wants to release insulin, but there are built-in brakes to keep this under control.
Glucose uptake and metabolism raise the ATP/ADP ratio, closing KATP channels and depolarizing the beta-cell, which triggers insulin granule exocytosis. Negative regulation of this process acts at multiple points to decrease the frequency, rate or extent of insulin release. This includes ion channels that repolarize the membrane and limit the duration of the excitatory burst, as well as downstream effectors that reduce granule fusion.
Ion channel-mediated dampening of excitability
In simple terms: Certain ion channels act like a dimmer switch, reducing the electrical signal that tells the cell to release insulin.
TRPM4 is a calcium-activated nonselective cation channel that controls insulin secretion in pancreatic beta-cells. Its activity modulates membrane potential and thereby reduces the extent of depolarization-driven insulin release. This represents a direct molecular mechanism for negative regulation of insulin secretion involved in cellular response to glucose stimulus.
Cytoskeletal and GTPase control of granule trafficking
In simple terms: The cell's internal skeleton and small molecular switches can hold granules back or slow their movement to the membrane.
The actin cytoskeleton and small GTPases regulate the access of insulin granules to the plasma membrane. Negative regulation can occur through stabilization of cortical actin that restricts granule docking, or through GTPase signaling that reduces granule mobilization. These mechanisms contribute to the biphasic nature of insulin exocytosis and can suppress the overall rate of release.
SNARE-dependent fusion and its negative modulation
In simple terms: The final step of insulin release uses SNARE proteins to fuse granules with the membrane, and this step can be slowed down.
SNARE proteins mediate the fusion of insulin granules with the plasma membrane. Negative regulation of insulin secretion can involve changes in SNARE complex formation or accessory proteins that reduce the efficiency of fusion. This provides a terminal checkpoint for decreasing the extent of glucose-stimulated insulin release.
Integration of negative signals
In simple terms: The cell combines multiple brake signals to fine-tune how much insulin is released.
The overall negative regulation of insulin secretion involved in cellular response to glucose stimulus is an integrated outcome of ion channel activity, cytoskeletal dynamics, GTPase signaling, and SNARE regulation. These layers ensure that insulin release is proportional to glucose and that excessive secretion is prevented. Disruption of any layer can shift the balance toward hyper- or hyposecretion.
Key Genes Involved in GO:0061179 negative regulation of insulin secretion involved in cellular response to glucose stimulus
The following genes and proteins are established or emerging players in the negative regulation of glucose-stimulated insulin secretion, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TRPM4 | Calcium-activated nonselective cation channel that modulates beta-cell membrane potential and dampens insulin secretion | Direct negative regulator of glucose-stimulated insulin release; target for hyperinsulinism studies |
| KCNJ11 | Kir6.2 subunit of KATP channel; controls beta-cell excitability | Mutations cause neonatal diabetes or hyperinsulinism; key node in secretion control |
| ABCC8 | SUR1 subunit of KATP channel; regulates channel activity | Major gene for congenital hyperinsulinism; modulates insulin secretion set point |
| GCK | Glucokinase; glucose sensor and rate-limiting step in glycolysis | Mutations alter glucose-stimulated insulin secretion threshold |
| SLC2A2 | GLUT2 glucose transporter; facilitates glucose uptake in beta-cells | Affects glucose sensing and downstream secretion |
| CACNA1C | Voltage-gated calcium channel; mediates calcium influx for exocytosis | Modulates strength of secretion stimulus |
| CACNA1D | Voltage-gated calcium channel; contributes to beta-cell calcium signaling | Candidate for secretion tuning |
| RAB3A | Small GTPase involved in insulin granule trafficking | Regulates granule mobilization and exocytosis |
| RAB27A | Small GTPase required for insulin granule docking and fusion | Loss impairs secretion; relevant to granule transport |
| STX1A | Syntaxin-1A; SNARE protein mediating granule fusion | Terminal effector of exocytosis; target for negative regulation |
| SNAP25 | SNARE protein; part of the fusion machinery | Modulates efficiency of insulin granule fusion |
| VAMP2 | Vesicle-associated membrane protein; SNARE on insulin granules | Key for fusion; its regulation can suppress secretion |
| ACTB | Beta-actin; major cytoskeletal component | Cortical actin restricts granule access; target for cytoskeletal control |
| CDC42 | Small GTPase regulating actin dynamics | Modulates cytoskeletal barrier to secretion |
| RAC1 | Small GTPase involved in actin remodeling | Contributes to granule trafficking control |
| PRKCZ | Protein kinase C zeta; signaling kinase | Potential modulator of secretion; context-dependent |
| INS | Insulin; the cargo of secretory granules | Mutations cause monogenic diabetes; feedback on secretion |
| PCSK1 | Prohormone convertase 1/3; processes proinsulin | Defects cause endocrine dysfunction and altered insulin secretion |
How Is negative regulation of insulin secretion involved in cellular response to glucose stimulus Regulated?
The negative regulation of insulin secretion involved in cellular response to glucose stimulus is itself regulated at multiple levels. Ion channel activity, particularly TRPM4, provides a dynamic brake that can be modulated by calcium and other signals. Cytoskeletal remodeling and small GTPase cycling are controlled by upstream signaling pathways that respond to glucose and other nutrients. SNARE complex assembly and disassembly are regulated by accessory proteins and post-translational modifications, providing additional checkpoints. Together, these regulatory layers ensure that insulin secretion is appropriately restrained during glucose stimulation.
negative regulation of insulin secretion involved in cellular response to glucose stimulus and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TRPM4 | Hyperinsulinism / beta-cell excitability | Knockout and point-mutation beta-cell lines; insulin secretion assays |
| ABCC8 | Congenital hyperinsulinism | Knockout iPSC-derived beta-cells; KATP channel function |
| KCNJ11 | Neonatal diabetes / hyperinsulinism | Point-mutation knock-in models; electrophysiology |
| GCK | Monogenic diabetes (MODY2) | Knock-in of patient mutations; glucose-stimulated insulin secretion |
| STX1A | Beta-cell exocytosis dysfunction | Knockout and rescue in insulinoma cells; SNARE assays |
Congenital hyperinsulinism
Loss of negative regulation of insulin secretion can cause congenital hyperinsulinism, characterized by excessive insulin release and hypoglycemia. Mutations in KATP channel genes such as ABCC8 and KCNJ11 are well-known causes, and other negative regulators like TRPM4 may contribute to the disease spectrum.
Type 2 diabetes
In type 2 diabetes, beta-cell dysfunction includes impaired first-phase insulin secretion and altered negative feedback. Dysregulation of ion channels, cytoskeletal dynamics, and SNARE-mediated exocytosis can contribute to inadequate insulin release relative to glucose levels.
Monogenic diabetes
Mutations in genes such as GCK and INS alter the glucose-stimulated insulin secretion set point. Negative regulatory pathways may modify disease severity, making them attractive targets for precision medicine.
From negative regulation of insulin secretion involved in cellular response to glucose stimulus-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase glucose-stimulated insulin secretion? | CRISPR knockout in pancreatic beta-cell lines (e.g., INS-1, MIN6) |
| Does a specific point mutation alter channel function and secretion? | Point-mutation knock-in via CRISPR in beta-cell lines or iPSCs |
| Does overexpression of a negative regulator suppress insulin release? | Overexpression cell models with doxycycline-inducible constructs |
| How does a tagged protein localize during glucose stimulation? | Tagged knock-in (e.g., GFP, HA) in beta-cells followed by imaging |
| Which genes are essential for negative regulation in a pooled format? | CRISPR library screening with insulin secretion readouts |
| What transcriptional networks control negative regulators? | RNA-seq and bioinformatics after CRISPR perturbation |
How to Study the negative regulation of insulin secretion involved in cellular response to glucose stimulus Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Static insulin secretion assay | Amount of insulin released over time | Screening for negative regulators in beta-cell lines |
| Dynamic perifusion | Real-time insulin release kinetics | Assessing first- and second-phase secretion |
| Patch-clamp electrophysiology | Ion channel activity and membrane potential | Studying TRPM4 and KATP channel function |
| TIRF microscopy | Granule docking and fusion events | Visualizing SNARE and cytoskeletal dynamics |
| RNA-seq | Transcriptional changes after perturbation | Identifying pathways co-regulated with insulin secretion |
| Proteomics | Protein abundance and modifications | Discovering novel negative regulators |
| CRISPR library screening | Pooled gene function in secretion | High-throughput discovery of negative regulators |
| Bioinformatics pathway analysis | Enrichment of GO terms and networks | Interpreting screening hits in the context of GO:0061179 |
Insulin secretion assays
Static and dynamic insulin secretion assays measure the amount of insulin released in response to glucose. These are the primary functional readouts for negative regulation of insulin secretion involved in cellular response to glucose stimulus. They can be coupled with CRISPR perturbations to test causality.
Electrophysiology
Patch-clamp recordings measure ion channel activity and membrane potential in beta-cells. This is essential for understanding how channels like TRPM4 dampen excitability and thereby reduce insulin secretion.
Imaging of granule trafficking
Live-cell imaging of fluorescently tagged insulin granules or SNARE proteins reveals how cytoskeletal and fusion machinery dynamics are altered during negative regulation. Total internal reflection fluorescence (TIRF) microscopy is particularly useful for studying granule docking and fusion.
Transcriptomics and proteomics
RNA-seq and proteomics can identify global changes in gene expression and protein abundance after CRISPR perturbation of candidate negative regulators. Bioinformatics integration helps place hits into pathways related to insulin secretion.
How CRISPR Can Be Used to Study GO:0061179 negative regulation of insulin secretion involved in cellular response to glucose stimulus
Knockout
CRISPR knockout is used to delete candidate negative regulators and test whether their loss increases glucose-stimulated insulin secretion. For example, knocking out TRPM4 in beta-cell lines can reveal its role in dampening secretion. Knockout models are also used in pooled screens to identify novel genes.
Point Mutation
Point-mutation knock-in via CRISPR allows researchers to model disease-associated variants in genes such as KCNJ11 or ABCC8. These models help determine whether a specific mutation alters the negative regulation of insulin secretion and contributes to hyperinsulinism or diabetes.
Knock-in
Tagged knock-in (e.g., GFP or HA) enables visualization of endogenous proteins involved in negative regulation, such as SNARE proteins or ion channels. This approach preserves native regulation and is ideal for imaging granule trafficking and protein localization.
Overexpression
CRISPR-based overexpression or cDNA overexpression models are used to test whether increasing the level of a candidate negative regulator suppresses insulin secretion. This is particularly useful for validating dose-dependent effects and for rescue experiments.
How EDITGENE Supports negative regulation of insulin secretion involved in cellular response to glucose stimulus Research
Researchers studying negative regulation of insulin secretion involved in cellular response to glucose stimulus-related genes often need to determine whether a candidate gene is causally involved in dampening insulin release or is merely correlated with the phenotype. EDITGENE provides the CRISPR tools and cell models required to move from correlation to causation in beta-cell research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of insulin secretion involved in cellular response to glucose stimulus research.
Frequently Asked Questions About negative regulation of insulin secretion involved in cellular response to glucose stimulus
What is GO:0061179?
GO:0061179 is a Gene Ontology biological_process term for any process that decreases the frequency, rate or extent of regulated insulin release that contributes to a cell's response to glucose.
What genes are involved in negative regulation of insulin secretion involved in cellular response to glucose stimulus?
Key genes include TRPM4, KCNJ11, ABCC8, GCK, and SNARE proteins such as STX1A and VAMP2, based on published literature.
How does TRPM4 regulate insulin secretion?
TRPM4 is a calcium-activated cation channel that modulates beta-cell membrane potential and dampens glucose-stimulated insulin secretion.
What is the role of SNARE proteins in insulin secretion?
SNARE proteins mediate the fusion of insulin granules with the plasma membrane, and their regulation can negatively control the extent of exocytosis.
Which diseases are linked to defective negative regulation of insulin secretion?
Congenital hyperinsulinism, type 2 diabetes, and monogenic diabetes are linked to defects in this process.
How can CRISPR be used to study GO:0061179?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in beta-cell lines and iPSC-derived beta-cells.
What methods measure negative regulation of insulin secretion?
Insulin secretion assays, electrophysiology, TIRF microscopy, RNA-seq, and proteomics are commonly used.
What is the difference between negative regulation of insulin secretion and GO:0061179?
GO:0061179 is the specific child term for negative regulation that occurs in the context of a cellular response to glucose.
Can CRISPR screens identify new negative regulators of insulin secretion?
Yes, pooled CRISPR screens with insulin secretion readouts can discover novel genes that dampen glucose-stimulated insulin release.
Why is negative regulation of insulin secretion important for diabetes research?
Because both excessive and insufficient negative regulation can lead to metabolic disease, making these pathways key therapeutic targets.
Conclusion
GO:0061179 provides a precise ontological framework for studying the cellular brakes on glucose-stimulated insulin secretion. The integration of ion channel biology, cytoskeletal dynamics, and SNARE-mediated exocytosis defines multiple layers of negative control that are essential for metabolic homeostasis. Dysregulation of these processes contributes to hyperinsulinism and diabetes, making them important research and therapeutic targets. CRISPR-based models from EDITGENE enable researchers to causally test candidate genes and accelerate discoveries in this field.
References
- 1. Wang Z et al.. 2009. Mechanisms of biphasic insulin-granule exocytosis - roles of the cytoskeleton, small GTPases and SNARE proteins.. J Cell Sci 122(Pt 7):893-903 PMID: 19295123
- 2. Cheng H et al.. 2007. TRPM4 controls insulin secretion in pancreatic beta-cells.. Cell Calcium 41(1):51-61 PMID: 16806463
